key: cord-0987421-ieh7vjnq
authors: Goswami, Ria; Russell, Veronica S.; Tu, Joshua J.; Thomas, Charlene; Hughes, Philip; Kelly, Francine; Langel, Stephanie N.; Steppe, Justin; Palmer, Scott M.; Haystead, Timothy; Blasi, Maria; Permar, Sallie R.
title: Oral Hsp90 inhibitor SNX-5422 attenuates SARS-CoV-2 replication and dampens inflammation in airway cells
date: 2021-11-10
journal: iScience
DOI: 10.1016/j.isci.2021.103412
sha: 874b049eaa8756621ebc792984e20b0f7bea798d
doc_id: 987421
cord_uid: ieh7vjnq

Currently available SARS-CoV-2 therapeutics are targeted towards moderately to severely ill patients and require intravenous infusions, with limited options for exposed or infected patients with no or mild symptoms. While vaccines have demonstrated protective efficacy, vaccine hesitancy and logistical distribution challenges will delay their ability to end the pandemic. Hence, there is a need for rapidly translatable, easy-to-administer-therapeutics, that can prevent SARS-CoV-2 disease progression, when administered in the early stages of infection. We demonstrate that an orally bioavailable Hsp90 inhibitor, SNX-5422, currently in clinical trials as an anti-cancer therapeutic, inhibits SARS-CoV-2 replication in vitro at a high selectivity index. SNX-5422 treatment of human primary airway epithelial cells dampened expression of inflammatory pathways previously associated with poor SARS-CoV-2 disease outcomes. Additionally, SNX-5422 interrupted expression of host factors demonstrated to be crucial for SARS-CoV-2 replication. Development of SNX-5422 as SARS-CoV-2-early-therapy will dampen disease severity, resulting in better clinical outcomes and reduced hospitalizations.

replication in vitro (Emanuel et al., 2020 , Li et al., 2020 , Kamel et al., 2020 . Here, we 126 sought to determine if an orally bioavailable, highly selective inhibitor of Hsp90 (SNX-5422) 127 (Okawa et al., 2009) , currently in clinical trials for cancer therapy (Infante et al., 2014, protein coding genes with a Log2 fold change (FC) ratio > 2 and adjusted p value ≤ 0.001. A 184 volcano plot of the protein coding genes indicated that 1361 genes were differentially 185 expressed between the two groups, with 470 cellular genes being upregulated and 891 186 cellular genes being downregulated upon SNX-5422 treatment ( Figure 2B ). To identify 187 cellular genes whose expression was highly regulated upon SNX-5422 treatment of TBE 188 cells, we collated DEGs with a Log2 FC >6, for which the average normalized read count 189 across donors and experimental conditions was ≥300 (Table S2 ). Using this stringent 190 threshold, we identified 16 cellular genes that were downregulated and 4 cellular genes 191 that were upregulated upon drug treatment ( Figure imbalanced upon infection. Our data indicate that of the 55 genes altered by treatment that were previously reported in the context of SARS-CoV-2 replication ( Figure  263 3A), 27 genes had an imbalanced cellular expression, in virally infected cells ( Figure 3C) . 264

Further categorization of these 55 genes revealed that the majority of these genes fall into 265 4 functional categories,-namely, regulators of innate immunity (SERPINA3 (D'Alessandro 266 et al., 2020) , BPIFA1 (Liu et al., 2020) , and PGLYRP4 (Chandrashekar et al., 2020) ), 267 regulators of cell cycle (UBE2C (Bock and Ortea, 2020) , CENPI (Venkatakrishnan et al., 268 2020) , BIRC5 (Xiong et al., 2020) , CCNB2 (Xiong et al., 2020) , BUB1B (Ahmed et al., 269 2020) , BUB1 (Ahmed et al., 2020) and CENPF (Gordon et al., 2020) ), mucosal structural 270 proteins (MMP9 (Hazra et al., 2020) and FCGBP (Liu et al., 2020) ) and regulators of blood 271 coagulation (SERPINA3 (D'Alessandro et al., 2020) , SERPINE1 (McCord et al., 2020) and 272 SERPINF2 (D'Alessandro et al., 2020) ). Furthermore, cellular genes whose expression was 273 impacted by SNX-5422 treatment, encoded for proteins that were previously shown to be 274 associated with SARS-CoV-2 replication phases (MMP9 (Hazra et al., 2020) and 275 SERPINE1 (McCord et al., 2020) ) or those interacting with SARS-CoV-2 structural and 276 non-structural proteins (BUB1B (Ahmed et al., 2020) , BUB1 (Ahmed et al., 2020) , CENPF 277 (Gordon et al., 2020) and ID1 (Islam and Khan, 2020) ). Taken together, our analysis 278 indicate that SNX-5422 treatment interrupted cellular pathways and genes associated with 279 replication of SARS-CoV-2. 280 281

CoV-2-infected human lung epithelial cells. 283 we sought to validate whether this anti-inflammatory mechanism of SNX-5422 was also 288 observed in SARS-CoV-2-infected human lung epithelial cells. To this end, Calu-3 cells 289

were incubated with SARS-CoV-2 strain USA-WA1/2020 for 1hr and the virus-exposed 290 cells were treated with 2.5µM SNX-5422 or DMSO (drug-vehicle) for 48 hrs. After 48hrs, 291 total cellular RNA was extracted, and relative gene expression of 5 pro-inflammatory genes 292 (CCL20, CXCL1, CXCL3, CXCL5 and CXCL6) identified to be downregulated by SNX-5422 293 in uninfected condition ( Figure 3B ) was assessed. SNX-5422 treatment downregulated 294 expression of all 5 genes compared to DMSO-treated controls in infected cell populations 295 ( Figure 3D ). Based on this finding, we postulate that early administration of SNX-5422 will 296 dampen SARS-CoV-2-mediated inflammation, although further validation of this hypothesis 297 in physiologically relevant ex vivo and in vivo models of infection will be necessary. 298

Viruses rely on the biosynthetic machinery of the host for their replication. Therefore, an 300 attractive strategy to attenuate viral propagation and mitigate poor disease outcomes is to 301 target viral host-dependency factors. While the advantage of such an antiviral strategy is 302 their efficacy against newly evolving viral variants and a high barrier towards development 303 of drug resistant viral strains, such therapies might interfere with the normal cellular 304 functioning. Hence, development of host-targeted therapeutics with very high selectivity index 305

for suppressing viral replication yet having minimal off-target effect is crucial. Moreover, as post-306 exposure prophylactics are administered to individuals with no-to-mild symptoms, the safety bar 307 for such a therapeutic modality will be higher than those administered in acutely infected 308 patients. Hence, while host-directed drug candidates are currently fast-tracked into clinical trials 309 as anti-SARS-CoV-2 therapeutics, characterizing the interactions of the drug candidates with 310 host cell mechanisms will be absolutely critical to minimize adverse outcomes.

skewing (De Biasi et al., 2020) , activation of the NF-κB signaling pathway (Huang et al., 2020b) , 314 and abnormal elevation of inflammatory cytokines (De Biasi et al., 2020) , leading to 315 hypercytokinemia and an imbalanced host immune response (Zhou et al., 2020a , Blanco-Melo 316 et al., 2020 . Hyperinflammation is a key determinant of the severity of COVID-19 outcomes 317 (Mehta et al., 2020) , where patients with higher levels of inflammatory cytokines have been 318 associated with higher risk of lung injury and ARDS (Chen et al., 2020, Torres Acosta and 319

Singer, 2020). Hence, targeted treatments, early during the course of infection, to prevent such 320 cytokine storms have been proposed (Gallelli et al., 2020) . We demonstrate that SNX-5422-321 treatment of human TBE cells downregulated key inflammatory pathways and genes already 322 associated with poor COVID-19 outcomes (Zhou et al., 2020a , Nienhold et al., 2020 . 323

Importantly, SNX-5422 treatment also altered expression of host responses reported to be 324 imbalanced upon SARS-CoV-2 infection such as innate immune responses (Blanco-Melo et al., 325 2020) , cell cycle regulation (Yuan et al., 2006) , biosynthesis and metabolism of amino acids 326 (Blasco et al., 2020) . Moreover, SNX-5422 interrupted expression of cellular factors that directly 327 or indirectly interact with the crucial steps of SARS-CoV-2 replication (McCord et al., 2020 , 328 Hazra et al., 2020 and with viral structural and non-structural proteins (Ahmed et al., , 329 Gordon et al., 2020 , Islam and Khan, 2020 . 330

In summary, our data support further testing and development of SNX-5422 as an oral 332 post-exposure prophylactic or early-phase therapeutic for SARS-CoV-2 infection. Based on 333 our findings, we hypothesize that early administration of SNX-5422 will interfere with SARS-334

CoV-2 replication machinery and dampen virus-induced inflammation and severe disease 335 outcomes. Our observations of the antiviral properties of SNX-5422 was primarily limited to 336

African green monkey kidney cells (Vero E6) and human lung epithelial (Calu-3) cell lines, 337 hence, experimental validation of such mechanisms in physiologically relevant ex vivo human The fact that SNX-5422 is orally bioavailable, and is clinically tested, makes this drug a 340 quality candidate for an easy-to-administer and rapidly translatable post-exposure 341

prophylactic therapy for SARS-CoV-2 infections. Of note, the in vitro drug levels necessary 342 for achieving SARS-CoV-2 suppression was very comparable to the anti-tumor drug levels 343 suggested in human phase II clinical trials (100mg/m 2 every other day, which is equivalent 344 to ~2.3µM plasma drug levels), although in vivo pharmacokinetic and pharmacodynamic 345 validation in SARS-CoV-2 infected conditions remains necessary. Finally, since SNX-5422 346 targets dependency factors that are utilized by multiple CoVs (Aldeyra Therapeutics Press 347

Release, , Emanuel et al., 2020 , Iyad et al., 2020 , Li et al., 2020 , Li et al., 2004 this 348 drug may have the potential to serve as a broad-spectrum ready-to-deploy therapeutic, which 349 might be efficacious in not only addressing the current pandemic, but also facilitating future 350 pandemic preparedness against newly emerging, genetically diverse, CoV strains. After 48 hr post-infection (pi), total RNA was extracted, and relative expression of selected 431 inflammatory genes were assessed using RT-qPCR. Two-sided p value was computed using 432

Welch's two-sample t test and statistical significance was evaluated at the 0.05 alpha level. (Table S1) for 5 minutes and infectious viral titer was measured by plaque assay as described above. 520 521 qRT-PCR. 522 SARS-CoV-2 RNA from cell supernatant was extracted using the QIAamp viral RNA mini kit 523 (Qiagen). A two-step qRT-PCR was used to detect viral RNA released in the cell supernatant. In 524 the first step, viral cDNA for the nucleocapsid (N) gene was generated using SuperScript™ III 525

First-Strand Synthesis System (Thermo Fisher) and N-reverse primer (5'-526 GAGGAACGAGAAGAGGCTTG-3'), following manufacturer's instructions. In the second step, 527 7uL cDNA from step-1 was amplified using N gene forward primer (5'-528 CACATTGGCACCCGCAATC-3'), N gene reverse primer (5'-GAGGAACGAGAAGAGGCTTG-529 expression mastermix (Thermo Fisher). The thermal cycling steps were: 50°C for 2 min, 95 °C 531 for 10 min, and 40 cycles of 95 °C for 15 s and 60 °C for 1 min, and qPCR was performed on a 532

Step-One-Plus real time PCR machine (Applied Biosystems) using the StepOne Software v2.3. 533 Viral RNA copy number/mL supernatant was assessed using pCDNA3.1(+)-N-eGFP plasmid 534 (Molecular Cloud/GenScript Biotech) as standard. 535

For extraction of total cellular RNA from SARS-CoV-2-infected Calu-3 cells, cells were 536 resuspended in TRIzol reagent (Thermo Fisher) followed by phase separation with chloroform 537 and cellular RNA was extracted subsequently using the RNeasy Mini Kit (Qiagen). A two-step 538 qRT-PCR was used to detect expression of selected cellular genes. In the first step, total cDNA 539 was generated using SuperScript™ III First-Strand Synthesis System (Thermo Fisher) and oligo 540 dT following manufacturer's instructions. In the second step, 8uL cDNA from step-1 was 541 amplified using TaqMan™ Gene Expression Master Mix and TaqMan Gene Expression 542

Assaysfor specific genes (Thermo Fisher). The thermal cycling steps were: 50°C for 2 min, 543 95 °C for 10 min, and 40 cycles of 95 °C for 15 s and 60 °C for 1 min, and qPCR was performed 544 on a Step-One-Plus real time PCR machine (Applied Biosystems) using the StepOne Software 545 v2.3. Relative expression of each target with respect to total input RNA quantity was computed. 546 547 Immunofluorescence assay. 1.4 X 10 5 Vero E6 or Calu-3 cells were seeded in 4-well chamber 548 slides (Corning). After 24 hrs, cells were incubated with SARS-CoV-2 USA-WA1/2020 strain at 549 an MOI of 0.01-0.02 at 37°C and 5% CO2, with intermittent rocking. After 1hr, the virus was 550 aspirated, cells were rinsed twice with 1X PBS and fresh maintenance medium containing 551 dilutions of SNX-5422 or Remdesivir or 0.1% DMSO was added. After 48hrs, cells were fixed by 552 submerging the chamber slides in 10% NBF for 2hrs. Fixed cells were washed three times with 553 DPBS (Sigma) + 0.02% Triton X-100. For immunostaining, cells were permeabilized with 554 DPBS+ 0.1% Triton-X-100 for 20 minutes and blocked in DPBS supplemented with 5% BSA, 555 at room temperature. After subsequent washing of the samples, the cells were treated with 558 Donkey anti-rabbit IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 488 559 (Thermo Fisher; 1:1000) for 1hr at room temperature. After further washing, the coverglasses 560 were mounted on glass slides with ProLong Glass Antifade with NucBlue (Invitrogen) and 561 sealed. Coverglasses were allowed to cure overnight prior to imaging using Axio Imager 562 fluorescent microscope (Carl Zeiss). Images were captured with 20X objective, processed using 563

Zeiss Zen Black software and proportion of SARS-CoV-2-NP+ cells were counted using Fiji (Yin 564 et al., 2021 , Schindelin et al., 2012 . To this end, a cut off threshold for both DAPI and AF-488 565 channel was computed in Fiji software based on uninfected cell images, and this threshold was 566 applied to Carl Zeiss Image metadata files for DMSO (drug-vehicle) or SNX-5422-treated 567 infected cells. The same threshold was maintained during quantification of each image from the 568 same experiment day. After the threshold was adjusted, positive cell counts in both channels 569 were documented using 'analyze particle' function in Fiji. Finally, percent NP+ cells were 570 computed from the evaluated cell counts from 5-10 fields per treatment condition each 571 experiment day. 572 573 CC50 and IC50 calculations. CC50 and IC50 were calculated using Fit spline/LOWESS 574 analysis in GrahPad prism, where we used the "point-to-point" curve fitting approach for 575 standard curve generation. 576 577 Bulk RNA-sequencing of human TBE cells. Human TBE cells from 3 independent donors 578 (Table S1) biotype mapping from the ENSEMBL annotation file. Prior to differential expression analysis, 598 count data was collapsed to donor level and genes for which mean raw count was at least 15 599 were kept. Normalization and differential expression were carried out with DESeq2 (Love et al., design formula was constructed to test for the effect of treatment while controlling for donor. 603 genes were generated using 'pheatmap' package in R. A vst was applied to count data, and 610 batch corrected with 'limma' package, followed by Z-score normalization. Dot plots 611 demonstrating upregulated and downregulated KEGG pathways were generated using 612 'ClusterProfiler' package in R using a "universe" of all human genes. Protein-protein interaction 613 (PPI) network was constructed using STRING Vs. 11.5 (Szklarczyk et al., 2021) and Cytoscape 614 (Vs 3.8.2) (Shannon et al., 2003) . as a Function of IL-6 Level. J Proteome Res, 19, [4417] [4418] [4419] [4420] [4421] [4422] [4423] [4424] [4425] [4426] [4427] 

Remdesivir for the Treatment of Covid-19 -Final Report

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

The specific metabolome profiling of patients infected by SARS-COV-2 674 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism

Re-analysis of SARS-CoV-2-infected host cell proteomics time-677 course data by impact pathway analysis and network analysis: a potential link with 678 inflammatory response

Identification of Required Host Factors for SARS-CoV-2 715 Infection in Human Cells

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients 722 with COVID-19 pneumonia

STAR: ultrafast universal RNA-seq 725 aligner

Scale-Up of an Hsp90 Inhibitor

Application of chemoproteomics to drug discovery: identification of a clinical candidate 743 targeting hsp90

Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways 747 activated by the virus, proposes unique sex-specific differences and predicts tailored 748 therapeutic strategies

Severe Acute Lung Injury

COVID-19 Infection: A Review and the Possible Role for Escin

HSP90 protects the human T-cell leukemia virus type 1 753 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-kappaB 754 activation and HTLV-1 replication

Broad action of Hsp90 as a host chaperone 756

Complex Immune Dysregulation in COVID-19 Patients with 767

Severe Respiratory Failure

Matrix 792 metallopeptidase 9 as a host protein target of chloroquine and melatonin for 793 immunoregulation in COVID-19: A network-based meta-analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

SARS-CoV-2 Infection of Pluripotent Stem 804

Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic 805

Orchestrating high-throughput 819 genomic analysis with Bioconductor

Phase I dose-escalation studies of SNX-5422, an orally 823 bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours

Lung transcriptome of a COVID-19 patient and systems biology 826 predictions suggest impaired surfactant production which may be druggable by 827 surfactant therapy

Drug Repositioning Suggests a Role for the 829

Heat Shock Protein 90 Inhibitor Geldanamycin in Treating COVID-19 Infection. 22 March

PB125(R) as a Potential Therapeutic Agent Against COVID-19. bioRxiv

Predictors 871 of mortality in patients with COVID-19-a systematic review

COVID-19: consider 875 cytokine storm syndromes and immunosuppression

Upper airway gene expression differentiates COVID-19 from 881

Comprehensive analysis of drugs to treat SARSCoV2 infection: Mechanistic 895 insights into current COVID19 therapies (Review)

Network perturbation analysis 898 in human bronchial epithelial cells following SARS-CoV2 infection

SARS-coronavirus-2 replication in Vero E6 cells: 903 replication kinetics, rapid adaptation and cytopathology

SNX-2112, a selective Hsp90 inhibitor

A phase I study 920 of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in 921 patients with refractory solid tumor malignancies and lymphomas

Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus 925 replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo

Fiji: an open-source platform for biological-image analysis

Cytoscape: a software environment for 934

An orally bioavailable broad-spectrum 945 antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple 946 coronaviruses in mice

Hsp90: a key target in HIV infection

Cytokine storm induced by SARS-CoV-2

The STRING database in 2021: customizable protein-protein networks, and 954 functional characterization of user-uploaded gene/measurement sets

phase via the cyclin D3/pRb pathway

Hsp90: a chaperone for protein folding and gene regulation

Neutralizing antibodies for the 1003 treatment of COVID-19

Heavy-tailed prior distributions for sequence 1005 count data: removing the noise and preserving large differences